2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-147300
    Puliginurad 2013582-27-7 99.96%
    Puliginurad (YL-90148) is a potent urate transporter (URAT) inhibitor. Puliginurad can be used for hyperuricemia and gout research.
    Puliginurad
  • HY-147377
    N-Salicyloyltryptamine 31384-98-2
    N-Salicyloyltryptamine acts on voltage-dependent Na+, Ca2+, and K+ ion channels inhibitor. N-Salicyloyltryptamine inhibits K+ currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect-.
    N-Salicyloyltryptamine
  • HY-147384
    CXL-1020 950834-06-7 ≥99.0%
    CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure.
    CXL-1020
  • HY-14779S
    Riociguat-13C,d6 99.0%
    Riociguat-13C,d6 is the 13C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
    Riociguat-13C,d6
  • HY-14806S
    Teneligliptin-d8 1391012-95-5 98%
    Teneligliptin-d8 is a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor.
    Teneligliptin-d8
  • HY-148147
    Metamizole 50567-35-6 98%
    Metamizol (Methamizole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.
    Metamizole
  • HY-148187
    NLRP3-IN-11 2769040-91-5 98.79%
    NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases.
    NLRP3-IN-11
  • HY-148292
    C16-Sphingosine-1-phosphate 709026-60-8 99.9%
    C16-Sphingosine-1-phosphate is a derivative of Sphingosine-1-phosphate and also an endogenous ligand for the EDG/S1P receptor. C16-Sphingosine-1-phosphate can be used in the research of angiogenesis, inflammation, and cardiovascular diseases.
    C16-Sphingosine-1-phosphate
  • HY-148529
    Midaglizole 66529-17-7 98.28%
    Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo.
    Midaglizole
  • HY-148687
    SPC5001
    SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′.
    SPC5001
  • HY-151350
    SphK2-IN-1 2927429-64-7 99.61%
    SphK2-IN-1 is a SphK2 inhibitor (IC50: 0.359 μM). SphK2-IN-1 can be used in the research of cancer, inflammation, neurological and cardiovascular disorders.
    SphK2-IN-1
  • HY-151369
    AV123 233605-81-7 99.60%
    AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC50=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC50=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases.
    AV123
  • HY-15193A
    EMD638683 (R-Form) 1184940-47-3 99.86%
    EMD638683 R-Form is the R-form of EMD638683 (HY-15193). EMD638683 is a highly selective SGK1 inhibitor.
    EMD638683 (R-Form)
  • HY-151959
    FXR agonist 4 3025841-47-5 99.37%
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD).
    FXR agonist 4
  • HY-15293A
    JTV-519 free base 145903-06-6 98%
    JTV-519 free base (K201 free base) is a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.
    JTV-519 free base
  • HY-153098
    ARC186
    ARC186 (sodium) is an unconjugated 40KDa PEG aptamer with a sequence identical to HY-147080 Avacincaptad pegol (ARC1905) sodium. ARC1905 is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.
    ARC186
  • HY-153463
    Diosuxentan 2305865-93-2 98%
    Diosuxentan is an inhibitor of ETA. Diosuxentan can be used in research for cardiovascular, renal and neuronal inflammation diseases.
    Diosuxentan
  • HY-15551A
    E-4031 free base 113558-89-7 98.92%
    E-4031 free base is a selective hERG potassium channel blocker for use in class III anti-arrhythmic studies.
    E-4031 free base
  • HY-156023
    SIRT1 activator 2 863589-52-0 99.28%
    SIRT1 activator 2 is a SIRT1 activator with an ED50 value <5 μM. SIRT1 activator 2 modulates SIRT1 deacetylase activity. SIRT1 activator 2 can be used for aging research.
    SIRT1 activator 2
  • HY-156501
    BT101 sodium
    BT101 (sodium), a complementary aptamer, has been developed to specifically inhibit BT100 function. BT100, a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis.
    BT101 sodium
Cat. No. Product Name / Synonyms Application Reactivity